BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21791474)

  • 1. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation.
    De Propris MS; Raponi S; Diverio D; Milani ML; Meloni G; Falini B; Foà R; Guarini A
    Haematologica; 2011 Oct; 96(10):1548-51. PubMed ID: 21791474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the
    Soare DS; Radu E; Dumitru I; Vlădăreanu AM; Bumbea H
    Leuk Lymphoma; 2021 Nov; 62(11):2716-2726. PubMed ID: 34034609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
    Falini B; Sportoletti P; Brunetti L; Martelli MP
    Br J Haematol; 2015 Aug; 170(3):305-22. PubMed ID: 25891481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
    Pollard JA; Alonzo TA; Gerbing RB; Woods WG; Lange BJ; Sweetser DA; Radich JP; Bernstein ID; Meshinchi S
    Blood; 2006 Oct; 108(8):2764-9. PubMed ID: 16809615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
    Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
    Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CD33 for acute myeloid leukemia therapy.
    Liu J; Tong J; Yang H
    BMC Cancer; 2022 Jan; 22(1):24. PubMed ID: 34980040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.
    Ehninger A; Kramer M; Röllig C; Thiede C; Bornhäuser M; von Bonin M; Wermke M; Feldmann A; Bachmann M; Ehninger G; Oelschlägel U
    Blood Cancer J; 2014 Jun; 4(6):e218. PubMed ID: 24927407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation.
    Arana Rosainz MJ; Nguyen N; Wahed A; Lelenwa LC; Aakash N; Schaefer K; Rios A; Kanaan Z; Chen L
    Int J Lab Hematol; 2021 Apr; 43(2):218-226. PubMed ID: 33099879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The surface molecular signature of leukemic cells is associated with NPM1 mutations and FLT3 -ITD in patients with de novo acute myeloid leukemia.
    Su L; Gao SJ; Li W; Tan YH; Cui JW; Han W
    Acta Haematol; 2014; 131(3):148-52. PubMed ID: 24192815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia.
    Park BG; Chi HS; Jang S; Park CJ; Kim DY; Lee JH; Lee JH; Lee KH
    Ann Hematol; 2013 Apr; 92(4):451-7. PubMed ID: 23238897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).
    Liso A; Castiglione F; Cappuccio A; Stracci F; Schlenk RF; Amadori S; Thiede C; Schnittger S; Valk PJ; Döhner K; Martelli MF; Schaich M; Krauter J; Ganser A; Martelli MP; Bolli N; Löwenberg B; Haferlach T; Ehninger G; Mandelli F; Döhner H; Michor F; Falini B
    Haematologica; 2008 Aug; 93(8):1219-26. PubMed ID: 18603563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleophosmin mutation in de-novo acute myeloid leukemia.
    Rastogi P; Naseem S; Varma N; Varma S
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):77-85. PubMed ID: 26669619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.
    Mori Y; Yoshimoto G; Kumano T; Miyamoto T; Iino T; Takenaka K; Iwasaki H; Harada N; Kinukawa N; Nagafuji K; Teshima T; Shimoda K; Akashi K; Harada M
    Eur J Haematol; 2007 Jul; 79(1):17-24. PubMed ID: 17598835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
    Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
    Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.